Pricing and reimbursement of multiple indication medicines: Can a balance be found between different stakeholder perspectives to optimise value and access for patients, while ensuring sustainable and affordable innovation?

This panel report explores pricing and reimbursement (P&R) of multiple medicines in Europe. Work has culminated from the panellists and audience of ~800 participants, where they discussed key challenges and forward-looking solutions for multi-indication products. The insights are captured in full within the report.

• Amanda Cole (University College London)
• Claudio Jommi (Universita del Piemonte Orientale)
• Julien Patris (argenx)

• Jens Grueger (BCG)

Click here to explore our ongoing work on multi-indication medicines